Wall Street Zen Upgrades Denali Therapeutics (NASDAQ:DNLI) to “Hold”

Denali Therapeutics (NASDAQ:DNLI) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Several other analysts also recently issued reports on the stock. Sanford C. Bernstein reissued a “hold” rating on shares of Denali Therapeutics in a research report on Monday, June 22nd. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. UBS Group lifted their price objective on shares of Denali Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a report on Friday. Wedbush reissued an “outperform” rating and set a $26.00 target price on shares of Denali Therapeutics in a research report on Monday, July 13th. Finally, Robert W. Baird set a $34.00 target price on shares of Denali Therapeutics in a research report on Friday. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $35.92.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock opened at $24.83 on Friday. Denali Therapeutics has a one year low of $12.58 and a one year high of $27.30. The firm has a market capitalization of $3.94 billion, a price-to-earnings ratio of -8.74 and a beta of 1.01. The business has a 50-day simple moving average of $23.54 and a 200 day simple moving average of $21.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The business had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $2.15 million. During the same period in the previous year, the business earned ($0.72) earnings per share. On average, research analysts anticipate that Denali Therapeutics will post -2.73 earnings per share for the current fiscal year.

Institutional Trading of Denali Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Denali Therapeutics during the 2nd quarter worth $26,000. Headlands Technologies LLC bought a new stake in Denali Therapeutics in the 2nd quarter valued at about $26,000. Global Retirement Partners LLC bought a new stake in Denali Therapeutics in the 2nd quarter valued at about $28,000. Johnson Financial Group Inc. purchased a new stake in Denali Therapeutics during the third quarter valued at about $29,000. Finally, State of Wyoming purchased a new stake in Denali Therapeutics during the second quarter valued at about $29,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.